Immix Biopharma, Inc. (IMMX)
Develops cell therapies to treat amyloidosis and immune diseases.
$8.44-0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+218.5%
The outlook
IMMX is trading near the middle of its 52-week range with analyst consensus at Strong Buy. The average price target sits roughly 136% above the current price, though the stock shows mixed momentum against its moving averages. Overall sentiment leans bullish based on current analyst ratings and valuation metrics.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 8 analysts
Price trendMixed vs its moving averages
52-week range64% of the way from its 52-week low to high
Price targetAvg target +136% vs current price
Analyst price target
~12-month · 8 analysts$19.91average target+135.9% vs now
Now $8.44
Low $14.50High $27.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$600.8M
52-wk high
$12.14
52-wk low
$1.94
50-day avg
$9.39
200-day avg
$7.29
Trailing P/E
—